Cargando…
Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and re...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308306/ https://www.ncbi.nlm.nih.gov/pubmed/37396144 http://dx.doi.org/10.3389/fpain.2023.1216190 |
_version_ | 1785066217632956416 |
---|---|
author | Gupta, Ashim Potty, Anish G. Maffulli, Nicola |
author_facet | Gupta, Ashim Potty, Anish G. Maffulli, Nicola |
author_sort | Gupta, Ashim |
collection | PubMed |
description | Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and relies on the utilization of biologics including platelet-rich plasma (PRP). Several peer-reviewed studies have documented the safety and efficacy of autologous PRP in mitigating symptoms in knee and hip OA patients. Nonetheless, only few studies investigated the safety and efficacy of allogenic PRP. This mini review summarizes the outcomes of preclinical and clinical studies using allogenic PRP for treatment of knee or hip OA. We identified 3 preclinical and 1 clinical study using allogenic PRP for treatment of knee OA, and only 1 clinical study using allogenic PRP for treatment of hip OA. Administration of allogenic PRP is safe and probably efficacious in patients with knee or hip OA. However, more pre-clinical studies and high-powered, multi-center, non-randomized and randomized controlled trials with extended follow-up are warranted to further establish the safety and efficacy of allogenic PRP to justify its clinical use. |
format | Online Article Text |
id | pubmed-10308306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103083062023-06-30 Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis Gupta, Ashim Potty, Anish G. Maffulli, Nicola Front Pain Res (Lausanne) Pain Research Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and relies on the utilization of biologics including platelet-rich plasma (PRP). Several peer-reviewed studies have documented the safety and efficacy of autologous PRP in mitigating symptoms in knee and hip OA patients. Nonetheless, only few studies investigated the safety and efficacy of allogenic PRP. This mini review summarizes the outcomes of preclinical and clinical studies using allogenic PRP for treatment of knee or hip OA. We identified 3 preclinical and 1 clinical study using allogenic PRP for treatment of knee OA, and only 1 clinical study using allogenic PRP for treatment of hip OA. Administration of allogenic PRP is safe and probably efficacious in patients with knee or hip OA. However, more pre-clinical studies and high-powered, multi-center, non-randomized and randomized controlled trials with extended follow-up are warranted to further establish the safety and efficacy of allogenic PRP to justify its clinical use. Frontiers Media S.A. 2023-06-15 /pmc/articles/PMC10308306/ /pubmed/37396144 http://dx.doi.org/10.3389/fpain.2023.1216190 Text en © 2023 Gupta, Potty and Maffulli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pain Research Gupta, Ashim Potty, Anish G. Maffulli, Nicola Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
title | Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
title_full | Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
title_fullStr | Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
title_full_unstemmed | Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
title_short | Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
title_sort | allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis |
topic | Pain Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308306/ https://www.ncbi.nlm.nih.gov/pubmed/37396144 http://dx.doi.org/10.3389/fpain.2023.1216190 |
work_keys_str_mv | AT guptaashim allogenicplateletrichplasmafortreatmentofkneeandhiposteoarthritis AT pottyanishg allogenicplateletrichplasmafortreatmentofkneeandhiposteoarthritis AT maffullinicola allogenicplateletrichplasmafortreatmentofkneeandhiposteoarthritis |